GlassScriptPhysician profile
Devang V Lodhavia
NPI 1679570634
$1,725.76
in general payments reported to CMS, 2019-2025
18 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $144 · 2021: $181 · 2022: $214 · 2023: $61.68 · 2024: $603 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009 · Education: $41.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.30 |
| Education | $41.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $567.67 | 2019-2023 | Veltassa |
| Ardelyx, INC. | $299.74 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.94 | 2023-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $115.97 | 2024-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $106.40 | 2022-2024 | Farxiga, Lokelma |
| Amgen INC. | $96.33 | 2019-2024 | Krystexxa |
| Akebia Therapeutics INC | $79.42 | 2022-2024 | Vafseo, Auryxia |
| Shield Therapeutics INC | $43.74 | 2024 | |
| Baxter Healthcare | $41.61 | 2024 | Renal - Pd |
| Travere Therapeutics, INC. | $32.34 | 2025 | Filspari |
| Apellis Pharmaceuticals, INC. | $32.15 | 2025 | Empaveli |
| Otsuka America Pharmaceutical, INC. | $31.33 | 2024 | Jynarque |
| Alnylam Pharmaceuticals INC. | $28.96 | 2025 | Givlaari |
| Calliditas Therapeutics US INC. | $28.49 | 2024 | |
| Glaxosmithkline, LLC. | $25.43 | 2020-2024 | Jesduvroq, Benlysta |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $17.97 | 2022 | |
| Pharmacosmos Therapeutics INC. | $13.27 | 2024 | Monoferric |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devang Lodhavia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.